Physician profile
Jitendra Sharma
NPI 1124251871
$4,295.04
in general payments reported to CMS, 2019-2025
32 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 76% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $145 · 2022: $723 · 2023: $718 · 2024: $567 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $650.33 | 2019-2025 | Target, Surpass Evolve, Trevo |
| Abbvie INC. | $522.51 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Eisai INC. | $347.96 | 2023-2025 | |
| Imperative Care, INC | $238.26 | 2024-2025 | Zoom 88-T Large Distal Platform |
| Medtronic, INC. | $211.47 | 2022-2025 | Solitaire X |
| Abbott Laboratories | $210.38 | 2023-2024 | Mitraclip, Acculink |
| Philips North America LLC | $202.44 | 2022-2023 | |
| Pfizer INC. | $190.83 | 2024-2025 | |
| Emd Serono, INC. | $188.53 | 2023-2024 | Mavenclad |
| Lilly USA, LLC | $176.27 | 2022-2025 | Kisunla |
| Alexion Pharmaceuticals, INC. | $153.03 | 2019-2025 | Ultomiris |
| Siemens Medical Solutions USA, INC. | $131.65 | 2022 | |
| Portola Pharmaceuticals, LLC | $130.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Lundbeck LLC | $122.13 | 2025 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $106.48 | 2025 | Briviact, Rystiggo |
| Xeris Pharmaceuticals, INC. | $88.06 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $83.52 | 2025 | Symbravo |
| Microvention, INC. | $79.02 | 2024-2025 | Stent, Web Aneurysm Embolization System, Sofia 6f-131cm Str |
| Biogen, INC. | $50.77 | 2024-2025 | Leqembi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.98 | 2025 | Rexulti |
| Inspiremd Ltd | $42.10 | 2025 | Cguard Prime Carotid Stent System |
| Argenx US, INC. | $38.63 | 2025 | Vyvgart Hytrulo |
| Penumbra, INC. | $32.26 | 2022 | |
| Ani Pharmaceuticals, INC. | $26.34 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $25.35 | 2019 | |
| Tanabe Pharma America, INC. | $23.46 | 2025 | Radicava |
| Acadia Pharmaceuticals INC | $20.41 | 2025 | Nuplazid |
| Amgen INC. | $19.34 | 2025 | Uplizna |
| Ceribell, INC. | $14.04 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitendra Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.